clinical trial · NCT04432584
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors
Hoffmann-La Roche·phase3·active not recruiting·n = 190
Paroxysmal Nocturnal HemoglobinuriaCrovalimabEculizumab
brief summary
A study designed to evaluate the safety of crovalimab with eculizumab in participants with PNH currently treated with complement inhibitors. This study will enroll approximately 190 participants.
started
Sep 30, 2020
primary completion
Sep 30, 2027
completion
Sep 30, 2027
last updated
Jan 28, 2026
official title
A Phase III, Randomized, Open-label, Active-controlled, Multicenter Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamic and Efficacy of Crovalimab Versus Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol